-
Product Insights
NewHeart Valve Disease – Drugs In Development, 2024
Empower your strategies with our Heart Valve Disease – Drugs In Development, 2024 report and make more profitable business decisions. Heart valve diseases are problems affecting one or more of the four valves in the heart, where the heart valve or valves do not open or close properly with every heartbeat, causing disruption of blood flow. Stenosis, regurgitation, and atresia are a few types of heart valve diseases. Signs and symptoms can range from mild to severe, including chest pain, irregular...
-
Product Insights
NewAortic Valve Diseases – Drugs In Development, 2024
Empower your strategies with our Aortic Valve Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Aortic Valve Disease (AVD) is a type of valve disease where hearts aortic valve does not work properly. Aortic valve controls the flow of blood from heart to all the body parts. When there is a damage to the aortic valve blood flow is affected. The 2 main aortic valve diseases are aortic stenosis and aortic regurgitation. In aortic stenosis blood...
-
Product Insights
NewAortic Valve Stenosis – Drugs In Development, 2024
Empower your strategies with our Aortic Valve Stenosis – Drugs In Development, 2024 report and make more profitable business decisions. Aortic valve stenosis (AVS) is caused by narrowing of the heart's aortic valve opening. The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully, which obstructs blood flow from the heart into the aorta and onward to the rest of the body. AVS can range from mild to severe. Signs and...
-
Product Insights
NewHuntington Disease – Drugs In Development, 2024
Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington...
-
Product Insights
Point of Care (POC) Analyzers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Point of Care (POC) Analyzers Pipeline Market Report Overview POC analyzers are small handheld or bench-top analyzers often used in small laboratories and physician labs with less workload and daily sample inflow. They often use disposable test cartridges and can provide faster results. The Point of Care (POC) analyzers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Curcumin + Doxorubicin) in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Curcumin + Doxorubicin) in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Curcumin + Doxorubicin) in Colorectal Cancer Drug Details: Imx-110...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: Zanidatamab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EU-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EU-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EU-101 in Non-Small Cell Lung Cancer Drug Details: EU-101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prp in Gastrointestinal Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prp in Gastrointestinal Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRP in Gastrointestinal Tract Cancer Drug Details:PRP is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII Deficiency)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII Deficiency) Drug Details:RG-6357 (SPK-8011, SPK-FVIII) is under development for...